Uniunea Europeană - română - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod clorhidrat de - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imunosupresoare - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

celgene distribution b.v. - olanda - ozanimodum - caps. - 0,23mg+0,46mg - imunosupresoare imunosupresoare selective

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

celgene distribution b.v. - olanda - ozanimodum - caps. - 0,92mg - imunosupresoare imunosupresoare selective